Biotherapeutics firm aTyr Pharma has received orphan drug designation from the European Commission (EC) for its Resolaris to treat facioscapulohumeral muscular dystrophy (FSHD).
Resolaris is a firm’s investigational new drug being developed as a first-in-class intravenous protein therapeutic to treat rare myopathies with an immune component.
Go deeper with GlobalData
It is derived from a naturally occurring protein released in-vitro by human skeletal muscle cells, noted aTyr Pharma.
aTyr Pharma CEO and executive chairman John Mendlein said: "Our mission is to develop medicines that will make a meaningful difference to patients impacted by debilitating rare diseases.
"We are very pleased that the EMA has recognised the potential of Resolaris for patients suffering from FSHD.
See Also:
"The agency’s decision is an important advancement for our promising Physiocrine-based medicines, and marks a key milestone in our strategy to deliver Resolaris to address the unmet needs of patients with this rare disease."
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company previously announced the first patient study of Resolaris in adults with FSHD, a rare and severe genetic myopathy, which there are currently no approved treatments for.
According to the company, the Phase Ib/II study is a double-blind, placebo-controlled and multiple ascending dose trial in up to 44 FSHD patients currently enrolling at multiple sites in the European Union (EU).
aTyr Pharma is involved in the development of Physiocrine-based therapeutics to provide solutions for rare diseases.
